Pages that link to "Item:Q7978"

← Introduction (Q7978)

What links here

Page:  Namespace:  all (Main) Talk User User talk Wikibase.slis.ua.edu Wikibase.slis.ua.edu talk File File talk MediaWiki MediaWiki talk Template Template talk Help Help talk Category Category talk Item Item talk Property Property talk Module Module talk   Invert selection

Filters

Hide transclusions | Hide links | Hide redirects

The following pages link to Introduction (Q7978):

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

• Introduction section from DOI: 10.3390/pathogens9020148 (Q7903) ‎ (← links)
• Introduction (Section from DOI: 10.1080/09273948.2020.1738501) (Q8063) ‎ (← links)
• Introduction section from DOI: 10.1186/s13613-020-00653-z (Q8290) ‎ (← links)
• Section 1: Introduction (from DOI: 10.1080/22221751.2020.1735265) (Q8394) ‎ (← links)
• Section 2: Protection requirements of medical personnel (from DOI: 10.1080/22221751.2020.1735265) (Q8395) ‎ (← links)
• Section 2.1: Selection of front-line personnel (from DOI: 10.1080/22221751.2020.1735265) (Q8396) ‎ (← links)
• Section 2.2: Isolation and protection requirements (from DOI: 10.1080/22221751.2020.1735265) (Q8397) ‎ (← links)
• Section 2.3: Isolation and observation of medical personnel after close contact with SARS-CoV-2 (from DOI: 10.1080/22221751.2020.1735265) (Q8398) ‎ (← links)
• Section 1: Introduction (from DOI: 10.1038/s41392-020-0110-5) (Q8462) ‎ (← links)
• Section 2: The concept of CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8463) ‎ (← links)
• Section 2.1: Biological characteristics of CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8464) ‎ (← links)
• Section 2.2: Isolation and identification of CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8465) ‎ (← links)
• Section 3: Factors regulating CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8466) ‎ (← links)
• Section 3.1: Major transcription factors in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8467) ‎ (← links)
• Section 3.2: Major signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8468) ‎ (← links)
• Section 3.2.1: Wnt signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8469) ‎ (← links)
• Section 3.2.2: Notch signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8470) ‎ (← links)
• Section 3.2.3: Hh signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8471) ‎ (← links)
• Section 3.2.4: NF-kappaB signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8472) ‎ (← links)
• Section 3.2.5: JAK-STAT signaling pathway (from DOI: 10.1038/s41392-020-0110-5) (Q8473) ‎ (← links)
• Section 3.2.6: TGF/SMAD signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8474) ‎ (← links)
• Section 3.2.7PI3K/AKT/mTOR signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8475) ‎ (← links)
• Section 3.2.8: PPAR signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8476) ‎ (← links)
• Section 3.2.9: Interactions between signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8477) ‎ (← links)
• Section 3.3: The microenvironment of CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8478) ‎ (← links)
• Section 3.3.1: Vascular niche microenvironments and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8479) ‎ (← links)
• Section 3.3.2: The hypoxia microenvironment and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8480) ‎ (← links)
• Section 3.3.3: Tumor-associated macrophages and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8481) ‎ (← links)
• Section 3.3.4: Cancer-associated fibroblasts and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8482) ‎ (← links)
• Section 3.3.5: Cancer-associated MSCs and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8483) ‎ (← links)
• Section 3.3.6: Extracellular matrix and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8484) ‎ (← links)
• Section 3.3.7: Exosomes in the TME and CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8485) ‎ (← links)
• Section 4: Therapeutic targeting of CSCs (from DOI: 10.1038/s41392-020-0110-5) (Q8486) ‎ (← links)
• Section 4.1: Agents targeting CSC-associated surface biomarkers in clinical trials (from DOI: 10.1038/s41392-020-0110-5) (Q8487) ‎ (← links)
• Section 4.2: Agents targeting CSC-associated signaling pathways in clinical trials (from DOI: 10.1038/s41392-020-0110-5) (Q8488) ‎ (← links)
• Section 4.3: Targeting the CSC microenvironment (from DOI: 10.1038/s41392-020-0110-5) (Q8489) ‎ (← links)
• Section 4.4: CSC-directed immunotherapy (from DOI: 10.1038/s41392-020-0110-5) (Q8490) ‎ (← links)
• Section 1. Introduction (from DOI: 10.3390/v12020211) (Q10062) ‎ (← links)
• Section 1: Introduction (from DOI: 10.1016/j.jcv.2020.104372) (Q10717) ‎ (← links)
• Section 2: Is SARS-CoV-2 a congenital or perinatally-acquired pathogen for the neonate? (from DOI: 10.1016/j.jcv.2020.104372) (Q10718) ‎ (← links)
• Section 2.1: Lessons from animal models (from DOI: 10.1016/j.jcv.2020.104372) (Q10719) ‎ (← links)
• Section 2.2: Congenital and perinatal infections with coronaviruses other than SARS-CoV-2 (from DOI: 10.1016/j.jcv.2020.104372) (Q10720) ‎ (← links)
• Section 2.3: Congenital and perinatal infections with SARS-CoV-2 (from DOI: 10.1016/j.jcv.2020.104372) (Q10721) ‎ (← links)
• Section 1: Introduction (from DOI: 10.1007/s11886-020-01292-3) (Q10734) ‎ (← links)
• Section 2: Biology of SARS-CoV-2 (from DOI: 10.1007/s11886-020-01292-3) (Q10735) ‎ (← links)
• Section 3: The Role of Host Immune Response (from DOI: 10.1007/s11886-020-01292-3) (Q10736) ‎ (← links)
• Section 4: Viral Toxicity and Myocardial Injury in COVID-2 (from DOI: 10.1007/s11886-020-01292-3) (Q10737) ‎ (← links)
• Section 5: Immune Responses to SARS-CoV-2 Infection and the Heart (from DOI: 10.1007/s11886-020-01292-3) (Q10738) ‎ (← links)
• Section 6: Host-Specific Variations in COVID-19 Immune Response (from DOI: 10.1007/s11886-020-01292-3) (Q10739) ‎ (← links)
• Section 1: Introduction (from DOI: 10.1186/s13054-020-02882-x) (Q10751) ‎ (← links)

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)